XML 37 R27.htm IDEA: XBRL DOCUMENT
v3.25.2

Revenue Recognition and Accounts Receivable (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2025
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue |
(In millions) | Three Months Ended June 30, 2025 (a)
Product Category | Developed Markets |  | Greater China |  | JANZ |  | Emerging Markets |  | Total
Brands | $ | 1,121.4 |  |  | $ | 586.5 |  |  | $ | 160.5 |  |  | $ | 416.1 |  |  | $ | 2,284.5 |
Generics | 997.9 |  |  | 2.4 |  |  | 145.2 |  |  | 139.0 |  |  | 1,284.5 |
Total Viatris | $ | 2,119.3 |  |  | $ | 588.9 |  |  | $ | 305.7 |  |  | $ | 555.1 |  |  | $ | 3,569.0 |
(In millions) | Six Months Ended June 30, 2025 (a)
Product Category | Developed Markets |  | Greater China |  | JANZ |  | Emerging Markets |  | Total
Brands | $ | 2,141.2 |  |  | $ | 1,139.3 |  |  | $ | 302.3 |  |  | $ | 818.6 |  |  | $ | 4,401.4 |
Generics | 1,869.8 |  |  | 5.1 |  |  | 279.5 |  |  | 256.4 |  |  | 2,410.8 |
Total Viatris | $ | 4,011.0 |  |  | $ | 1,144.4 |  |  | $ | 581.8 |  |  | $ | 1,075.0 |  |  | $ | 6,812.2 |
(In millions) | Three Months Ended June 30, 2024
Product Category | Developed Markets |  | Greater China |  | JANZ |  | Emerging Markets |  | Total
Brands | $ | 1,233.8 |  |  | $ | 535.7 |  |  | $ | 198.4 |  |  | $ | 395.2 |  |  | $ | 2,363.1 |
Generics | 1,085.4 |  |  | 3.3 |  |  | 151.2 |  |  | 182.9 |  |  | 1,422.8 |
Total Viatris | $ | 2,319.2 |  |  | $ | 539.0 |  |  | $ | 349.6 |  |  | $ | 578.1 |  |  | $ | 3,785.9 |
(In millions) | Six Months Ended June 30, 2024
Product Category | Developed Markets |  | Greater China |  | JANZ |  | Emerging Markets |  | Total
Brands | $ | 2,412.6 |  |  | $ | 1,077.5 |  |  | $ | 382.5 |  |  | $ | 799.6 |  |  | $ | 4,672.2 |
Generics | 2,072.0 |  |  | 5.4 |  |  | 284.9 |  |  | 404.9 |  |  | 2,767.2 |
Total Viatris | $ | 4,484.6 |  |  | $ | 1,082.9 |  |  | $ | 667.4 |  |  | $ | 1,204.5 |  |  | $ | 7,439.4 |
The following table presents net sales on a consolidated basis for select key products for the three and six months ended June 30, 2025 and 2024, respectively:
|  | Three Months Ended June 30, |  | Six Months Ended June 30,
(In millions) |  | 2025 |  | 2024 |  | 2025 |  | 2024
Select Key Global Products |  |  |  |  |  |  |  |
Lipitor ® |  | $ | 387.9 |  |  | $ | 348.4 |  |  | $ | 775.9 |  |  | $ | 737.3 |
Norvasc ® |  | 182.7 |  |  | 161.9 |  |  | 355.0 |  |  | 338.2 |
EpiPen® Auto-Injectors |  | 136.8 |  |  | 115.5 |  |  | 233.5 |  |  | 195.7 |
Lyrica ® |  | 128.1 |  |  | 124.3 |  |  | 240.7 |  |  | 238.5 |
Viagra ® |  | 100.3 |  |  | 106.1 |  |  | 198.8 |  |  | 206.8 |
Creon ® |  | 91.4 |  |  | 78.2 |  |  | 173.8 |  |  | 153.2 |
Celebrex ® |  | 70.0 |  |  | 72.2 |  |  | 133.4 |  |  | 144.4 |
Effexor ® |  | 63.1 |  |  | 62.7 |  |  | 122.4 |  |  | 122.1 |
Zoloft ® |  | 61.1 |  |  | 58.9 |  |  | 121.3 |  |  | 116.9 |
Xalabrands |  | 40.7 |  |  | 45.6 |  |  | 77.8 |  |  | 88.1 |
Select Key Segment Products |  |  |  |  |  |  |  |
Yupelri ® |  | $ | 66.6 |  |  | $ | 54.5 |  |  | $ | 124.9 |  |  | $ | 109.7 |
Dymista ® |  | 48.4 |  |  | 55.0 |  |  | 91.2 |  |  | 103.2 |
Amitiza ® |  | 41.6 |  |  | 36.9 |  |  | 74.9 |  |  | 69.9 |
Xanax ® |  | 33.9 |  |  | 35.4 |  |  | 66.2 |  |  | 69.9 |
____________ (a)The Company does not disclose net sales for any products considered competitively sensitive. (b)Products disclosed may change in future periods, including as a result of seasonality, competition or new product launches. (c)Amounts for the three and six months ended June 30, 2025 include the impact of foreign currency translations compared to the prior year period. (d)Refer to intellectual property matters included in Note 17 Litigation for additional information regarding Yupelri® and Amitiza®.
Disaggregation of Revenue, Variable Consideration | The following table presents a reconciliation of gross sales to net sales by each significant category of variable consideration during the three and six months ended June 30, 2025 and 2024, respectively:
| Three Months Ended |  | Six Months Ended
| June 30, |  | June 30,
(In millions) | 2025 (a) |  | 2024 |  | 2025 (a) |  | 2024
Gross sales | $ | 5,974.8 |  |  | $ | 6,383.9 |  |  | $ | 11,545.0 |  |  | $ | 12,558.5 |
Gross to net adjustments: |  |  |  |  |  |  |
Chargebacks | (1,260.6) |  |  | (1,282.6) |  |  | (2,418.6) |  |  | (2,526.8) |
Rebates, promotional programs and other sales allowances | (918.4) |  |  | (1,040.5) |  |  | (1,889.0) |  |  | (2,088.8) |
Returns | (47.8) |  |  | (70.1) |  |  | (102.1) |  |  | (130.4) |
Governmental rebate programs | (179.0) |  |  | (204.8) |  |  | (323.1) |  |  | (373.1) |
Total gross to net adjustments | $ | (2,405.8) |  |  | $ | (2,598.0) |  |  | $ | (4,732.8) |  |  | $ | (5,119.1) |
Net sales | $ | 3,569.0 |  |  | $ | 3,785.9 |  |  | $ | 6,812.2 |  |  | $ | 7,439.4 |
___________ (a)Amounts for the three and six months ended June 30, 2025 include the Indore Impact and the impact of foreign currency translations and divested businesses compared to the prior year period.
Schedule of Accounts Receivable, Net | Such allowances were comprised of the following at June 30, 2025 and December 31, 2024, respectively:
(In millions) | June 30, 2025 |  | December 31, 2024
Accounts receivable, net | $ | 1,417.8 |  |  | $ | 1,547.0 |
Other current liabilities | 1,046.3 |  |  | 989.4 |
Total | $ | 2,464.1 |  |  | $ | 2,536.4 |
Accounts receivable, net was comprised of the following at June 30, 2025 and December 31, 2024, respectively:
(In millions) | June 30, 2025 |  | December 31, 2024
Trade receivables, net | $ | 2,794.2 |  |  | $ | 2,675.3 |
Other receivables | 463.9 |  |  | 546.0 |
Accounts receivable, net | $ | 3,258.1 |  |  | $ | 3,221.3 |

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disaggregation of Revenue, Variable Consideration + References No definition available. + Details
Name: | vtrs_DisaggregationOfRevenueVariableConsiderationTableTextBlock
Namespace Prefix: | vtrs_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration